Advertisement

International Journal of Hematology

, Volume 106, Issue 5, pp 591–611 | Cite as

JSH guideline for tumors of hematopoietic and lymphoid tissues—lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN)

  • Noriko UsuiEmail author
Guide Line

Overview

Myeloproliferative neoplasms (MPN), a group of diseases that develop through neoplastic transformation at the level of hematopoietic stem cells, are characterized by marked proliferation of myeloid cells (i.e., granulocytes, erythroblasts, megakaryocytes, and mast cells) [1]. The category of MPN includes chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), mastocytosis, and myeloproliferative neoplasms, unclassifiable (MPN, U). Early stage MPN exhibit hyperplasia of bone-marrow cells with capacity for differentiation and increased peripheral granulocytes, red blood cells (RBCs), and platelets. Physical findings include splenomegaly and hepatomegaly. MPN produce few subjective symptoms at onset, but progress in stages along with general symptoms. They ultimately progress to bone-marrow failure, the fatal...

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of Transfusion Medicine/Clinical Oncology and HematologyThe Jikei University Daisan HospitalKomaeJapan

Personalised recommendations